Biogen has received FDA approval for Aduhelm, a drug used to treat Alzheimer’s treatment. In what has been one of the most closely watched green lights of the year, Aduhelm’s approval includes all Alzheimer’s patients meaning millions of potential patients may be eligible for the drug.

The treatment is a monthly IV infusion. The cost looks be $56,000/year which could generate $10 billion in sales and one of the biggest launches in biopharmaceutical history. This cost is much higher than experts had previously estimated. The Institute for Clinical and Economic Review suggested the cost should be $8,300/year and several analysts had estimated the drug would cost around $10,000 per year.

Click here to view the entire article.